Welcome to our dedicated page for Kazia Therapeuti news (Ticker: KZIA), a resource for investors and traders seeking the latest updates and insights on Kazia Therapeuti stock.
Kazia Therapeutics Limited develops clinical-stage oncology therapies through an Australian foreign-issuer structure whose American depositary shares trade under KZIA. Company news centers on paxalisib, a brain-penetrant dual PI3K/mTOR inhibitor being developed across brain cancer and advanced breast cancer indications, including triple-negative breast cancer studies that report clinical and translational findings.
Recurring updates also cover Kazia's broader oncology platform, including NDL2, a PD-L1 protein degrader platform, and MSETC, a SETDB1-targeted epigenetic program. Additional company developments include research leadership, licensing activity, financing and capital-structure actions, Nasdaq listing compliance, annual meeting matters, governance changes, and operating or financial results.
Kazia Therapeutics Limited (NASDAQ: KZIA) announced final data from its Phase II study of paxalisib for glioblastoma at ASCO 2022. The study involved 30 patients and found a median overall survival (OS) of 15.7 months, exceeding the 12.7 months reported for temozolomide. Median progression-free survival (PFS) was 8.6 months, significantly higher than the 5.3 months for the current standard of care. The maximum tolerated dose was determined to be 60mg once daily, with a safety profile consistent with previous studies. The company looks forward to further development based on these encouraging results.
Kazia Therapeutics Limited (NASDAQ: KZIA) announced the opening of recruitment for the paxalisib arm of the GBM AGILE study in Europe, specifically at University Hospital Zurich. This marks the first European clinical trial activity for paxalisib, which is part of a larger effort to find effective treatments for glioblastoma. Over 40 sites in the U.S. and Canada are already recruiting for this study, which aims to evaluate overall survival as a primary endpoint. The trial's duration is expected to be 30-36 months, with final data anticipated by the end of 2023.
Kazia Therapeutics is focusing on childhood brain cancer, leveraging its experience from adult brain cancer treatments. The company is addressing significant challenges in enrolling patients for clinical trials, creating a gap in treatment options. Despite limited data, Kazia is positioned to pioneer this niche market. Their current net present value is estimated at US$294m (US$22.28 per basic ADR). As of December 2021, Kazia reported net cash of US$11.0m and anticipates needing approximately US$51m in additional financing to support operations through 2024.
Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) announced that CEO Dr. James Garner will present at two investor conferences. The first is the HC Wainwright Global Investment Conference in Miami, FL, from May 23-26, 2022, where he will discuss upcoming news from Kazia's clinical programs. The second is the LD Micro Invitational XII in Westlake Village, CA, from June 7-9, 2022, focusing on the company's licensing strategy and progress on paxalisib, its lead program targeting glioblastoma. Institutional investors can register for one-on-one meetings.
Kazia Therapeutics Limited (NASDAQ: KZIA) acknowledges 'DIPG Awareness Day' on May 17, 2022, highlighting the urgent need for increased awareness and research funding for childhood brain cancer, especially diffuse intrinsic pontine glioma (DIPG). This type of cancer has no FDA-approved treatment and a median survival of 9-11 months. Kazia's investigational drug, paxalisib, is under a phase II study for DIPG, with data expected in 2023. New preclinical data will be presented at the ISPNO Conference in June 2022, emphasizing the potential of paxalisib in offering hope to affected families.
Kazia Therapeutics Limited (NASDAQ: KZIA) announced the final data from its phase II study of paxalisib for newly diagnosed glioblastoma will be presented at the ASCO Annual Meeting from June 3-7, 2022, in Chicago, IL. The poster titled 'Paxalisib in patients with newly diagnosed glioblastoma' will take place on June 5, 2022. Abstracts will be released on May 26, 2022. Kazia specializes in oncology and is advancing paxalisib, recognized for its efficacy against brain tumors, alongside other therapies like EVT801.
Kazia Therapeutics Limited (NASDAQ: KZIA) announced promising preclinical data on paxalisib, showcased in three abstracts at the AACR Annual Meeting. The findings highlight paxalisib's efficacy in treating childhood brain cancers, particularly atypical teratoid/rhabdoid tumors (AT/RT) and diffuse intrinsic pontine glioma (DIPG), both of which lack FDA-approved therapies. Notably, paxalisib demonstrated survival benefits when combined with other cancer treatments. The ongoing phase II clinical trial in DIPG furthers its potential. Kazia aims to explore wider applications for paxalisib in pediatric brain cancers.
Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) announced two poster presentations at the AACR Annual Meeting in New Orleans, detailing the phase I study of EVT801, a VEGFR3 inhibitor targeting advanced cancer. The study aims to assess safety, tolerability, and pharmacokinetics while employing innovative biomarker strategies to identify effective patient profiles. EVT801 is a promising candidate licensed from Evotec and commenced patient recruitment in November 2021, with initial data expected in the second half of 2022.
Kazia Therapeutics announces progress in its pivotal GBM AGILE study for lead asset paxalisib, with data expected in CY23. Recent US C-suite appointments indicate a focus on commercialization. The second asset, EVT801, is in human trials, with the first patient enrolled in France. The company's valuation has increased to US$294m or US$22.28 per basic ADR, driven by NPV roll-forward, despite lower cash and higher R&D costs. Net cash stood at US$11.0m as of December 31, 2021, indicating a runway into H123.
Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) announced upcoming presentations at two key events. Scheduled for April 8-13, 2022, at the American Association of Cancer Research Annual Scientific Meeting in New Orleans, four abstracts related to their drug pipeline will be presented. This includes updates on EVT801 and paxalisib, both pivotal in treating advanced cancers. Additionally, CEO Dr. James Garner will discuss corporate progress at the 2022 Virtual Growth Conference from March 28-30, 2022. These presentations highlight Kazia's commitment to oncology research and drug development.